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X-linked liver glycogenosis (XLG), also known as glycogen storage disease type-IXa, 
is characterized by hepatomegaly, abnormal liver functions and growth retarda-
tion. It is caused by mutations in the PHKA2 gene that encodes the α-subunit of 
phosphorylase kinase (PHK). XLG can be divided into two subtypes: XLG-I, with a 
deficiency in PHK activity in peripheral blood cells and the liver; and XLG-II, with 
normal PHK activity in vitro. This report describes two boys who presented with 
hepatomegaly and abnormal liver function. Pedigree analysis revealed them to be 
fifth-degree relatives, with the disease transmitted through undiagnosed grandfathers. 
Liver histology confirmed GSD diagnosis, and both cases had a deficiency in PHK 
activity in red blood cells and liver tissues. This is the first report of XLG-I in the 
ethnic-Chinese population in Taiwan. This report indicates that XLG may be undiag-
nosed or underestimated. A correct diagnosis is necessary for proper management 
and genetic counseling.
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1.  Introduction
X-linked liver glycogenosis (XLG), also known as 
glycogen storage disease (GSD) type-IXa, results 
from a genetic deficiency of hepatic phosphorylase 
kinase (PHK) activity. PHK plays an important role 
in glycogen metabolism by activating glycogen 
phosphorylase for the degradation of glycogen to 
glucose-1-phosphate, and consists of four copies 
of four subunits each (α, β, γ and δ) to form a tet-
radecameric structure. The γ subunit harbors cata-
lytic activity, which is activated by phosphorylation 
of the α and β subunits and the interaction of Ca2+ 
with the δ subunit. Mutations of PHKA1 and PHKA2 
genes on the X chromosome, which encodes the 
muscle and liver isoforms of the α subunit, cause 
glycogen storage disease (GSD) type-IXc and type-
IXa, respectively.1 XLG can be divided into two 
subtypes: XLG-I, with a deficiency in PHK activity 
in peripheral blood cells and liver tissues; and 
XLG-II, with normal in vitro PHK activity in eryth-
rocytes and leukocytes and low enzyme activity in 
the liver.2,3 The differences between XGL-I and 
XGL-II led to the hypothesis that mutations in the 
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PHKA2 gene in XLG-I disrupt the region of the α 
subunit that interacts with the catalytic subunit of 
PHK, whereas mutations in XLG-II might affect the 
hydrolytic activity of the PHK α subunit.4 
The main symptoms of both types of XLG are 
hepatomegaly, growth retardation, elevated as-
partate aminotransferase (AST) and alanine ami-
notransferase (ALT) levels, hypercholesterolemia, 
and hypertriglyceridemia. Unlike other types of GSD, 
XLG is generally a benign disease. Muscles with XLG 
are clinically and enzymatically normal, which is dif-
ferent from GSD type-IXc. The clinical symptoms 
gradually improve with age, and patients are often 
asymptomatic in adulthood.5 Mutations of PHKA2 
have been reported in Western countries and Japan. 
However, there are no previous reports of XLG in 
the Chinese or Taiwanese population. Here, we re-
port a family with XLG-I.
2.  Case Reports
2.1.  Case 1
A 4-year, 7-month-old boy, with a birth weight of 
3,050 g and birth length of 50 cm, presented with 
abdominal distention and general malaise for 1 year. 
Physical examination revealed marked hepatome-
galy, with a liver span of 7.5 cm below the right cos-
tal margin, and growth retardation, with a body 
height of 95 cm (3rd to 10th percentile), and a body 
weight of 17 kg (50th to 75th percentile). His develop-
ment was normal, and neurological examinations 
revealed no abnormalities. He had been treated as 
non A-to-C hepatitis for 1.5 years, with fluctuating 
liver enzyme levels. His mother claimed no family 
history of hepatitis. The boy’s hemogram was nor-
mal. Blood biochemistry showed elevated liver 
enzymes, with AST 317 U/L and ALT 362 U/L, triglycer-
ides 170 mg/dL, total cholesterol 181 mg/dL, creatine 
phosphokinase (CK) 145 U/L, uric acid 5.5 mg/dL 
and normal bilirubin and blood sugar levels. There 
was no metabolic acidosis. Serum markers for viral 
hepatitis were all negative. Abdominal sonography 
revealed marked hepatomegaly, with a liver span of 
11 cm at the right mid-clavicle line and 11 cm at the 
mid-sternal line, with homogeneously increased echo-
genicity. Liver histology (Figure 1A) showed diffuse 
clear cytoplasm in hepatocytes, which were positively 
stained for periodic acid-Schiff and negatively for 
diastase-resistant periodic acid-Schiff. Electron mi-
croscopic examination revealed glycogen filling in 
the cytoplasm of hepatocytes. Glycogen storage dis-
ease was diagnosed according to clinical and patho-
logical findings. After a 4-year follow-up, the patient 
had mild hepatomegaly and intermittent mild 
elevation of ALT.
2.2.  Case 2
A 1-year, 3-month-old boy was transferred to our hos-
pital by his family physician due to hepatomegaly. 
His birth weight and height were 3,480 g and 49 cm, 
respectively, at a gestational age of 38 weeks. 
Growth retardation, with a body height of 75 cm 
(3rd−10th percentile) and a body weight of 9.9 kg 
(25th−50th percentile), was noted. Neurological de-
velopment and examinations were normal. The par-
ents denied any other affected individuals in the 
family. Blood biochemistry revealed abnormal liver 
enzymes, AST 138 U/L and ALT 151 U/L, triglycerides 
83 mg/dL, total cholesterol 123 mg/dL, CK 110 U/L, 
uric acid 4.9 mg/dL and normal bilirubin and sugar 
levels. Hepatomegaly with homogeneous increased 
echogenicity was noticed on abdominal sonography. 
Liver histology and electron microscopy confirmed 
the diagnosis of glycogen storage disease (Figure 1B). 
After a 3-year follow-up, the patient’s liver func-
tion tests became normal and mild hepatomegaly 
persisted.
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Figure 1 Liver histology of cases 1 (A) and 2 (B) show diffuse clear cytoplasm in the hepatocytes and hepatocyte 
ballooning change (hematoxylin and eosin; A: 40˜; B: 200˜).
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2.3.  Family history
Six months after Case 2 was diagnosed with glycogen 
storage disease, the mothers of both children, who 
were cousins, discovered that their children had 
similar diseases. A detailed pedigree was determined 
and suggested an X-linked inheritance (Figure 2). 
In addition to the two patients, the maternal grand-
father of Case 2 had been diagnosed with hepatitis 
in childhood. His present body length was 150 cm, 
which is below the Taiwanese average range. Liver 
enzymes were normal at this time, and abdominal 
sonography showed negative findings. The mater-
nal grandfather of Case 1 also had short stature at 
150 cm, without history of liver disease.
2.4.  PHK activity
The suspected X-linked inheritance of these two pa-
tients led us to consider type-IX GSD. Enzymatic 
tests of PHK activity on red blood cells and liver tis-
sues in both patients were performed by the Duke 
University School of Medicine. Briefly, rabbit muscle 
phosphorylase was added as an exogenous substrate 
to detect endogenous PHK activity in erythrocytes 
and liver tissues. PHK activity deficiency could be 
detected by decreased phosphorylase ratios. In our 
cases, all tissues revealed no PHK activity compared 
with positive controls. Although we intended to per-
form enzyme assays for the two grandfathers, they 
refused to undergo the test.
2.5.  PHKA2 gene mutation analysis
Genomic DNA was isolated from peripheral blood 
leukocytes using the Puregene DNA isolation kit 
(Gentra, Minneapolis, MN, USA). PCR amplification 
of selected exons (exons 4, 6, 9, 26, 32 and 33) of the 
PHKA2 gene (Genbank accession number NP_000283) 
was performed using the primer sets described in 
previous reports.6 The PCR products were sub-
jected to direct DNA sequencing. Sequence analysis 
was performed by dideoxynucleotide chain termi-
nation using the ABI 377 DNA Automated Sequencer 
(Applied Biosystems, Foster City, CA, USA). No mu-
tations of these exons were noted in either patient.
3.  Discussion
Both cases in this study presented with hepatome-
galy, abnormal liver function and short stature, 
but no evidence of hypoglycemia. Both cases later 
showed spontaneous improvements in liver func-
tion. Therefore, a mild form of glycogen storage 
disease, such as GSD type-III or type-IX, was sus-
pected. The family history strongly suggested an 
X-linked inheritance leading to a final diagnosis of 
XLG-I, which was confirmed by enzymatic tests. To 
our knowledge, this is the first report of Taiwanese 
patients with GSD type-IXa. Our report emphasizes 
the importance of establishing complete and de-
tailed family history in diagnosing metabolic and 
genetic diseases. A detailed pedigree is needed to 
elucidate the inheritance patterns. 
The main symptoms of XLG include hepatome-
galy and abnormal liver enzyme levels. The clini-
cal symptoms are generally benign. Hypoglycemia 
and metabolic acidosis, two symptoms that are fre-
quently observed in most of the other types of GSD, 
are rarely seen in XLG. Initial growth retardation has 
been noted between the ages of 2−10 years. Subjects 
often approach normal height in adulthood.7 Further-
more, clinical symptoms gradually disappear with 
age, leaving most adults asymptomatic. Because it 
is difficult to classify these patients, many have 
probably been diagnosed incorrectly. The prevalence 
rates are probably underestimated due to the be-
nign presentation. No large-scale studies assessing 
the incidence and prevalence of XLG have been pub-
lished. The two maternal grandfathers of our pa-
tients were suspected to be affected, because of the 
history of hepatitis and short stature. Because indi-
viduals with XLG may be asymptomatic in adulthood, 
it is difficult to reach a clinical diagnosis; the disease 
passes to descendents through undiagnosed males.
In the English literature, 43 patients with XLG-I 
and 16 with XLG-II have been reported to have 33 
and 13 different PHKA2 gene mutations, respec-
tively.6,8−21 We failed to identify a mutation in our 
cases after sequencing exons 4, 6, 9, 26, 32 and 33, 
which cover 45.5% (15/33) of the reported mutation 
sites and 48.8% (21/43) of cases with XLG-I. The 
genetic defects in our cases may be located in 
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Figure 2 Pedigree of the two cases. Cases 1 and 2 were available for genomic analysis. Both maternal grandfathers 
of these patients (upper filled squares) were undiagnosed, according to their short stature and previous history 
of abnormal liver enzymes, suggesting an X-linked inheritance.  = female;  = male;  = obligate female carrier; 
 = case;    = deceased.
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uncommon sites that warrant further investigation. 
It is possible that ethnic groups have diverse muta-
tions because different mutations have been noted 
in Dutch, French and Japanese patients. 
Some types of GSD have been reported to be 
complicated by hepatic adenoma, hepatocellular 
carcinoma, acute myelogenous leukemia and neu-
tropenia during follow-up.22−24 No associated dis-
eases or malignancies have been reported with type 
IX GSD. Most asymptomatic patients with XLG are 
undiagnosed. Long-term follow-up of our patients 
is necessary to monitor and determine regression 
in liver disease with age and any associated meta-
bolic complications.
3.  Conclusions
In summary, we report the first family diagnosed 
with XLG-I in Taiwan. Careful collection of clinical 
and pathological evidence, as well as detailed fam-
ily histories, is essential for diagnosis. Because this 
is a relatively benign form of GSD, many cases are 
probably undiagnosed and the prevalence rate is 
therefore underestimated. XLG should be consid-
ered in cases of idiopathic hepatopathy and short 
stature in children or adults. Further genetic stud-
ies to identify the mutations in Taiwanese patients 
should be performed to confirm the molecular 
basis for these patients.
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